PHILADELPHIA, PA -- FDA is aiming to gauge whether it can use data from real-world evidence from unstructured electronic health records and insurance claims to monitor patients’ responses to cannabis and cannabis-derived products -- with results from an initial test of the approach, which if successful could potentially be expanded to other products, expected in spring 2025. Sarah Dutcher, lead epidemiologist at FDA’s Sentinel Innovation Center, explained the project at the Drug Information Association’s Real World Evidence conference on Oct...